VitriVax

Colorado-based biotech VitriVax announced Wednesday it has raised an undisclosed amount of Series A financing from Adjuvant Capital to develop and commercialize its Atomic Layering Thermostable Antigen and Adjuvant (ALTA) technology which reformulates vaccines for extended shelf life and can compress multidose regimens into a single shot.

The ALTA platform works by protecting antigens and adjuvants against thermal and chemical degradation at temperatures up to 70 degrees Celsius “for…